Endo Partners With US Government On Critical Medicines

Par Unit Will Expand Sterile Fill-Finish Manufacturing Capacity At Its Rochester Facility

Endo subsidiary Par Sterile Products will expand its Rochester, Michigan facility to begin the fill-finish manufacturing of both mRNA and adenovirus vaccines. Around three-quarters of the project’s expected $120m total costs are being funded by the US government as part of larger efforts to boost the country’s domestic supply of essential medicines.

USA Flag Handshake Business Deal
Endo has struck a deal with the US government • Source: Alamy

Endo subsidiary Par Sterile Products has entered into an agreement with the US government to expand its sterile fill-finish manufacturing production capacity and capabilities at its Rochester, Michigan plant to support national pandemic preparation efforts. The government will fund approximately $90m of the program’s expected total cost of around $120m.

The agreement has been made following efforts from the Department of Defense to address vulnerabilities in critical product supply chains...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business